SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549


SCHEDULE 13G

Under the Securities Exchange Act of 1934


Stemline Therapeutics, Inc.
(Name of Issuer)
 
Common Stock
(Title of Class of Securities)
 
85858C107
(CUSIP Number)
 
December 31, 2019
(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

          X   Rule 13d-1(b)
 
 

Rule 13d-1(c)

 
 

Rule 13d-1(d)

*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

Page 1 of 8



CUSIP No. 85858C107

1

NAME OF REPORTING PERSON

Manulife Financial Corporation

                
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a)
(b)
               
N/A
 
3 SEC USE ONLY
 
 
4

CITIZENSHIP OR PLACE OF ORGANIZATION

Canada

  
Number of
Shares
Beneficially
Owned by
Each
Reporting
Person
With
5 SOLE VOTING POWER
                
-0-
 
6 SHARED VOTING POWER
  
-0-
 
7 SOLE DISPOSITIVE POWER
 
-0-
 
8 SHARED DISPOSITIVE POWER
 
-0-
 
9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
  
None, except through its indirect, wholly-owned subsidiaries, Manulife Investment Management (US) LLC and Manulife Investment Management Limited
 
10 CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*
 
N/A
 
11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
 
See line 9 above.
 
12 TYPE OF REPORTING PERSON*
 
HC
 

*SEE INSTRUCTIONS

Page 2 of 8



CUSIP No. 85858C107

1

NAME OF REPORTING PERSON

Manulife Investment Management (US) LLC

                
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a)
(b)
               
N/A
 
3 SEC USE ONLY
 
 
4

CITIZENSHIP OR PLACE OF ORGANIZATION

Delaware

  
Number of
Shares
Beneficially
Owned by
Each
Reporting
Person
With
5 SOLE VOTING POWER
                
2,559,069
 
6 SHARED VOTING POWER
  
-0-
 
7 SOLE DISPOSITIVE POWER
 
2,559,069
 
8 SHARED DISPOSITIVE POWER
 
-0-
 
9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
  
2,559,069
 
10 CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*
 
N/A
 
11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
 
5.10%
 
12 TYPE OF REPORTING PERSON*
 
IA
 

*SEE INSTRUCTIONS

Page 3 of 8



CUSIP No. 85858C107

1

NAME OF REPORTING PERSON

Manulife Investment Management Limited

                
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a)
(b)
               
N/A
 
3 SEC USE ONLY
 
 
4

CITIZENSHIP OR PLACE OF ORGANIZATION

Canada

  
Number of
Shares
Beneficially
Owned by
Each
Reporting
Person
With
5 SOLE VOTING POWER
                
27,905
 
6 SHARED VOTING POWER
  
-0-
 
7 SOLE DISPOSITIVE POWER
 
27,905
 
8 SHARED DISPOSITIVE POWER
 
-0-
 
9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
  
27,905
 
10 CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*
 
N/A
 
11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
 
0.06%
 
12 TYPE OF REPORTING PERSON*
 
FI
 

*SEE INSTRUCTIONS

Page 4 of 8



Item 1(a) Name of Issuer:
                         Stemline Therapeutics, Inc.
 
Item 1(b) Address of Issuer's Principal Executive Offices:
750 Lexington Avenue, 11th Floor
New York, New York 10022
 
Item 2(a) Name of Person Filing:
This filing is made on behalf of Manulife Financial Corporation ("MFC") and MFC’s indirect, wholly-owned subsidiaries, Manulife Investment Management (US) LLC ("MIM (US)") and Manulife Investment Management Limited ("MIML”)
  
Item 2(b) Address of Principal Business Office:
The principal business offices of MFC and MIML are located at 200 Bloor Street East, Toronto, Ontario, Canada, M4W 1E5.
The principal business office of MIM (US) is located at 197 Clarendon Street, Boston, Massachusetts 02116.
 
Item 2(c) Citizenship:
MFC and MIML are organized and exist under the laws of Canada.
MIM (US) is organized and exists under the laws of the State of Delaware.
 
Item 2(d) Title of Class of Securities:
Common Stock
 
Item 2(e) CUSIP Number:
85858C107
 
Item 3 If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
 
  MFC: (g) (X)    a parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G).
   
  MIM (US): (e) (X) an investment adviser in accordance with §240.13d-1(b)(1)(ii)(E).
     
  MIML: (j) (X) a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J).

Item 4 Ownership:
 
                         (a) Amount Beneficially Owned: MIM (US) has beneficial ownership of 2,559,069 shares of Common Stock and MIML has beneficial ownership of 27,905 shares of Common Stock. Through its parent-subsidiary relationship to MIM (US) and MIML, MFC may be deemed to have beneficial ownership of these same shares.
   
  (b) Percent of Class: Of the 50,129,326 shares of Common Stock outstanding as of November 12, 2019, according to the Form 10-Q filed by the issuer with the Securities and Exchange Commission on November 12, 2019, MIM (US) held 5.10% and MIML held 0.06%.

Page 5 of 8



                         (c) Number of shares as to which the person has:
 
(i) sole power to vote or to direct the vote:
MIM (US) and MIML each has sole power to vote or to direct the voting of the shares of Common Stock beneficially owned by each of them.
 
(ii) shared power to vote or to direct the vote: -0-
 
(iii) sole power to dispose or to direct the disposition of:
MIM (US) and MIML each has sole power to dispose or to direct the disposition of the shares of Common Stock beneficially owned by each of them.
 
(iv) shared power to dispose or to direct the disposition of: -0-
 
Item 5 Ownership of Five Percent or Less of a Class:
Not applicable.
 
Item 6 Ownership of More than Five Percent on Behalf of Another Person:
Not applicable.
 
Item 7 Identification and Classification of the Subsidiary which Acquired the Security Being Reported on by the Parent Holding Company or Control Person:
See Items 3 and 4 above.
 
Item 8 Identification and Classification of Members of the Group:
Not applicable.
 
Item 9 Notice of Dissolution of Group:
Not applicable.
 
Item 10 Certification:
By signing below the undersigned certifies that, to the best of its knowledge and belief, (i) the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, and (ii) the foreign regulatory schemes applicable to MIML, are substantially comparable to the regulatory scheme applicable to the functionally equivalent U.S. institutions. The undersigned also undertakes to furnish to the Commission staff, upon request, information that would otherwise be disclosed in a Schedule 13D.

Page 6 of 8


SIGNATURE

After reasonable inquiry and to the best of its knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

Manulife Financial Corporation
 
By: /s/ Susie Rafael
Name:      Susie Rafael
Dated: January 24, 2020 Title: Agent*
 
Manulife Investment Management (US) LLC
 
By: /s/ Paul Donahue
Name: Paul Donahue
Dated: January 27, 2020 Title: Chief Compliance Officer
 
Manulife Investment Management Limited
 
By: /s/ Christopher Walker
Name: Christopher Walker
Dated: January 22, 2020 Title: Chief Compliance Officer

* Signed pursuant to a Power of Attorney dated January 17, 2018 included as Exhibit A to Schedule 13F-NT filed with the Securities and Exchange Commission by Manulife Financial Corporation on January 29, 2018.

Page 7 of 8


EXHIBIT A

JOINT FILING AGREEMENT

Manulife Financial Corporation, Manulife Investment Management (US) LLC and Manulife Investment Management Limited agree that the Schedule 13G to which this Agreement is attached, relating to the Common Stock of Stemline Therapeutics, Inc., is filed on behalf of each of them.

Manulife Financial Corporation
 
By: /s/ Susie Rafael
Name:      Susie Rafael
Dated: January 24, 2020 Title: Agent*
 
Manulife Investment Management (US) LLC
 
By: /s/ Paul Donahue
Name: Paul Donahue
Dated: January 27, 2020 Title: Chief Compliance Officer
 
Manulife Investment Management Limited
 
By: /s/ Christopher Walker
Name: Christopher Walker
Dated: January 22, 2020 Title: Chief Compliance Officer

* Signed pursuant to a Power of Attorney dated January 17, 2018 included as Exhibit A to Schedule 13F-NT filed with the Securities and Exchange Commission by Manulife Financial Corporation on January 29, 2018.

Page 8 of 8